Skip to main content

Table 3 Prevalence of MS with respect to drug combination

From: Prevalence of metabolic syndrome in human immunodeficiency virus - infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria

Drug combination (n)

MS (%)

Lamivudine/Zidovudine/Nevirapine (35)

6 (17.1%)

Lamivudine/Zidovudine/Efavirens (15)

5 (33.3%)

Lamivudine/Stavudine/Nevirapine (6)

3 (50%)

Lamivudine/Stavudine/Efavirens (6)

1 (16.7%)

Lopinavir/Ritonavir/ Lamivudine/Zidovudine (17)

2 (11.8%)

Lopinavir/Ritonavir/Tenofovir/Lamivudine (14)

0 (0%)

Lopinavir/Ritonavir/Tenofovir/Emtricitabine (19)

3 (15.8%)

  1.  = First-line drug combination  = Second-line drug combination n = number.